Novartis’ chronic lung disease drug wins approval in EU, Japan

Novartis obtained approval from the European Commission to market its once-daily Ultibro Breezhaler, or QVA149, as a maintena -More- Free Worksheet Helps Weigh Factors in Deciding to Go Back…
Read the full story: BIO SmartBrief